HK Stock Market Move | IMPACT THERAP-B (07630) surged nearly 13% as its core product, Senapali, rapidly increased in volume. Being included in the Hang Seng Composite Index is expected to drive further growth.

IMPACT THERAP-B (07630) rose nearly 13%, and as of the time of this report, it was up 11.14%, trading at HK$14.87, with a transaction volume of HK$5.1481 million. In terms of news, Inspur Pharmaceutical announced this morning that the board was informed by the company's executive director and CEO, Cai Suixiong, that he has recently purchased a total of 100,000 shares of the company's common stock in the open market, at an average price of approximately HK$14.6105 per share, accounting for about 0.035% of the company's total issued shares. Dr. Cai expressed his confidence in the overall development prospects and potential growth of the group. Furthermore, the company has been included in the Hang Seng Composite Index, with the changes effective after market close on September 4 and effective from September 7. The company's shares are expected to meet the standards for inclusion in the Stock Connect programs. In the first half of this year, Inspur Pharmaceutical achieved revenue of HK$105 million, a year-on-year increase of 316.8%; the net loss narrowed by 29.5% year-on-year. Notably, the core product Senapali has experienced rapid growth since being included in the national medical insurance drug list on January 1 of this year, with sales revenue from Senapali in China reaching HK$70.4 million in the first half of the year, a year-on-year increase of 877.8%. It has now covered all provinces in Mainland China and nearly 1,200 medical institutions.